Volcano, ev3 sign distribution agreement
This article was originally published in The Gray Sheet
Volcano enters a three-year agreement, under which its 80-rep U.S. sales team will sell ev3's SpiderFX embolic protection device in conjunction with Volcano's intravascular ultrasound and functional measurement devices for use in saphenous vein grafts. Financial details of the arrangement, announced April 3, were not disclosed. ev3, which also makes stents and catheters, will continue to sell SpiderFX for SVG and carotid indications. The same day, ev3 announced first quarter sales of $61.5 million, a 46% increase over the prior-year period...
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.